Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.
Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 5.58 Increased by +12.50% | 5.11 Increased by +9.20% |
| Aug 6, 24 | 4.97 Decreased by -0.60% | 5.01 Decreased by -0.80% |
| May 2, 24 | 3.96 Decreased by -0.50% | 3.87 Increased by +2.33% |
| Feb 6, 24 | 4.71 Increased by +15.16% | 4.61 Increased by +2.17% |
| Oct 31, 23 | 4.96 Increased by +5.53% | 4.67 Increased by +6.21% |
| Aug 3, 23 | 5.00 Increased by +7.53% | 4.49 Increased by +11.36% |
| Apr 27, 23 | 3.98 Decreased by -6.35% | 3.85 Increased by +3.38% |
| Jan 31, 23 | 4.09 Decreased by -6.19% | 4.10 Decreased by -0.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 8.50 B Increased by +23.18% | 2.83 B Increased by +63.58% | Increased by +33.28% Increased by +32.80% |
| Jun 30, 24 | 8.33 B Increased by +19.28% | 746.00 M Decreased by -45.90% | Increased by +8.95% Decreased by -54.65% |
| Mar 31, 24 | 7.40 B Increased by +21.15% | -113.00 M Decreased by -103.98% | Decreased by -1.53% Decreased by -103.28% |
| Dec 31, 23 | 8.20 B Increased by +19.84% | 767.00 M Decreased by -52.54% | Increased by +9.36% Decreased by -60.40% |
| Sep 30, 23 | 6.90 B Increased by +3.77% | 1.73 B Decreased by -19.27% | Increased by +25.06% Decreased by -22.21% |
| Jun 30, 23 | 6.99 B Increased by +5.94% | 1.38 B Increased by +4.71% | Increased by +19.74% Decreased by -1.17% |
| Mar 31, 23 | 6.11 B Decreased by -2.13% | 2.84 B Increased by +92.48% | Increased by +46.54% Increased by +96.67% |
| Dec 31, 22 | 6.84 B Decreased by -0.10% | 1.62 B Decreased by -14.90% | Increased by +23.63% Decreased by -14.82% |